Viewing Study NCT00794495


Ignite Creation Date: 2025-12-24 @ 1:41 PM
Ignite Modification Date: 2025-12-27 @ 10:36 PM
Study NCT ID: NCT00794495
Status: COMPLETED
Last Update Posted: 2022-02-17
First Post: 2008-11-19
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)
Sponsor: Organon and Co
Organization:

Study Overview

Official Title: Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis
Status: COMPLETED
Status Verified Date: 2022-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Zyrtec, the patient prefers more.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: